These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 4555831)

  • 1. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):100-3. PubMed ID: 4555826
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
    Kazamatsuri H; Chien CP; Cole JO
    Am J Psychiatry; 1973 Apr; 130(4):479-83. PubMed ID: 4570750
    [No Abstract]   [Full Text] [Related]  

  • 4. Methylphenidate in tardive dyskinesia.
    Fann WE; Davis JM; Wilson IC
    Am J Psychiatry; 1973 Aug; 130(8):922-4. PubMed ID: 4577471
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic approaches to tardive dyskinesia. A review of the literature.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Oct; 27(4):491-9. PubMed ID: 4116201
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacology of tardive dyskinesias.
    Klawans HL
    Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa.
    Kazamatsuri H; Cole JO
    Arch Gen Psychiatry; 1972 Dec; 27(6):824-7. PubMed ID: 4637899
    [No Abstract]   [Full Text] [Related]  

  • 8. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
    Rubovits R; Klawans HL
    Arch Gen Psychiatry; 1972 Oct; 27(4):502-7. PubMed ID: 5072718
    [No Abstract]   [Full Text] [Related]  

  • 10. Tetrabenazine in the treatment of extrapyramidal dyskinesias.
    Gilligan BS; Wodak J; Veale JL; Munro OR
    Med J Aust; 1972 Nov; 2(19):1054-6. PubMed ID: 4264609
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs].
    Ferrari P; Robotti E; Nardini M
    Boll Chim Farm; 1972 Oct; 111(10):610-5. PubMed ID: 4566407
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention and management of tardive dyskinesia.
    Crane GE
    Am J Psychiatry; 1972 Oct; 129(4):466-7. PubMed ID: 5071149
    [No Abstract]   [Full Text] [Related]  

  • 13. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spontaneous oral dyskinesia. Successful treatment with tetrabenazine (author's transl)].
    Schumm F; Dichgans J; Zeller E
    Arch Psychiatr Nervenkr (1970); 1981; 230(4):315-23. PubMed ID: 7316728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethylbenzatropine for acute neurological and mental side effects after tranquillisers.
    Molcan J; Floreánová L; Polák L
    Act Nerv Super (Praha); 1972; 14(2):97. PubMed ID: 5040183
    [No Abstract]   [Full Text] [Related]  

  • 16. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J; Orman J
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both.
    Pakkenberg H; Fog R
    Arch Neurol; 1974 Nov; 31(5):352-3. PubMed ID: 4607088
    [No Abstract]   [Full Text] [Related]  

  • 18. Tardive dyskinesia.
    Simpson GM
    Br J Psychiatry; 1973 May; 122(570):618. PubMed ID: 4717040
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 20. The neuroleptics. 10. Therapeutic problems.
    Barahona-Fernandes HJ; Cazzullo CL; Cocchi A; Denber HC; Freyhan FA; Klerman GL; Köknel O; Levine J; Saarma J; Sarteschi P; Vinar O; Wittenborn JR
    Mod Probl Pharmacopsychiatry; 1970; 5():148-56. PubMed ID: 4949818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.